Objective: To assess in a longitudinal study whether subjective cognitive decline (SCD) and brain b-amyloid (Ab) contribute unique information to cognitive decline.
Alzheimer disease (AD) is preceded by a long preclinical period characterized by neuropathology without accompanying symptoms 1, 2 and the accumulation of b-amyloid (Ab) plaques in the cerebral cortex. 1, 3 Because clinical trials of Ab-lowering therapies have consistently failed in symptomatic people, several large clinical trials are recruiting cognitively intact people with evidence of brain Ab to treat a preclinical phase of AD. 4 Because this preclinical phase can last decades and clinical trials cannot, there is a critical need to identify markers that indicate a high risk of converting to a symptomatic phase of AD.
Both Ab plaques, which can be measured in vivo with PET, 5 and subjective cognitive decline (SCD), the subjective report of one's own cognition decline over time, 6 are highly relevant to longitudinal cognitive change. The presence and extent of both brain Ab 1, 3, 7 and SCD [8] [9] [10] [11] at baseline are associated with cognitive decline over time, although associations with the latter are sometimes confounded by disparities in definition 6 and the presence of neuropsychiatric deficits, 12 which themselves may be independently associated with cognitive decline. 13 While brain Ab and SCD are frequently concurrent phenomena, [14] [15] [16] little is known about how these factors are related to one another and to longitudinal cognitive change. For example, it is unclear whether SCD and Ab exert independent additive effects on cognitive outcomes or if 1 factor is a principal driver of predicting cognitive change. In addition, assessing both Ab and SCD may be more informative than measuring either alone; individuals with SCD but without Ab may be experiencing cognitive or affective changes that are not due to preclinical AD, while individuals with Ab but without SCD may be at lesser risk of imminent decline. Measuring both factors may increase power to detect cognitively intact individuals at greatest risk for incipient dementia.
In this longitudinal study, we measured brain Ab and SCD in 136 healthy older people who were followed up for a mean of 4 years and were undergoing regular cognitive assessment. We used mixed models to ascertain the independent and interactive effects of SCD and Ab on cognition over time. Given the potential role of depressive symptoms in AD and cognitive decline, 13 we also tested models examining the relationship between these 2 variables. We hypothesized that SCD and Ab would exert additive effects on cognition such that individuals exhibiting evidence for both markers would demonstrate the steepest cognitive decline.
METHODS Participant characteristics. Participants made up a sample of 346 cognitively intact elderly individuals from the Berkeley Aging Cohort Study (BACS). Information about recruitment and inclusion criteria is reported elsewhere. 17 All participants demonstrated intact cognition at baseline, evidenced by a score $25 on the Mini-Mental State Examination 18 and .1.5 SDs below the age-, sex-, education-adjusted population mean for 2 delayed recall memory tests (California Verbal Learning Test Long Delay Free Recall and Wechsler III Visual Recall Long Delay Free Recall). Finally, all participants were required to score #10 on the Geriatric Depression Scale (GDS) 19 and were thus considered to be nondepressed. Each participant underwent at least 1 standardized interview and neuropsychological testing procedure assessing health and demographic information, lifestyle factors, family history of AD, and multiple domains of cognition.
The entire cohort was used to develop variables that measured SCD and other measures of cognitive function. A subsample of 136 participants with all data on or before November 13, 2015, was used for all subsequent analyses. Demographics from this sample can be found in table 1. Participants were followed up from 1 to 10 years (table 1) , amounting to a total of 519 observations across all participants.
Standard protocol approvals, registrations, and patient consents. Informed consent was obtained at each assessment and before all scanning protocols, and all procedures were approved by the Institutional Review boards of the University of California, Berkeley and the Lawrence Berkeley National Laboratory.
Measurement of SCD and affective variables. Previous
literature has variably demonstrated that cognitive complaint is a principal component of the GDS. 20, 21 We extracted a latent measure of SCD by performing a principal axis factor analysis with direct oblimin rotation on a tetrachoric correlation matrix 22 generated from 29 yes/no questions from the GDS at baseline using the Psych package from R (http://cran.r-project.org/ package5psych). One question, "Do you feel that your situation is hopeless?," was excluded from the analysis because 0% of the sample endorsed this statement. Each yes/no question was dummy coded so that the "depressed" answer was equal to 1. Parallel analysis 23 suggested a 4-factor solution, which included a factor that grouped questions assessing cognitive complaints and was called SCD ( figure 1A ). Factor loadings and weights for each question can be found in tables e-1 and e-2 at Neurology.org, respectively. The resulting SCD factor scores were generated for each participant with regression. Factor scores from the remaining 3 factors (interpreted as dysphoric mood, anxiety, and apathy/ hopelessness) were averaged to create 1 variable, affective score, representing negative affect. Scores were computed at the baseline visit. A simple command-line executable function to convert GDS scores into these factor scores can be found at https:// github.com/illdopejake/Neurology_2017_SCD_score. Measurement of cognition. Cognitive factor scores were derived from the baseline sample as previously described 24 and validated. 25 Cognitive factors included episodic memory, executive function, and processing speed (table e-3). Factor scores were calculated for each participant at each time point by applying factor weights derived from the whole sample to z-scored cognitive test scores. Global cognition scores were generated by averaging all 3 cognitive factor scores.
Imaging. PET scans were acquired an average of 1.02 years (SD 5 1.61 years) after cognitive baseline. Structural MRI scans were acquired with a Siemens 1.5T Magnetom Avanto system (Siemens Medical Systems, Iselin, NJ) using a 12 channel headcoil run in triple mode. Details of the acquisition procedures have been documented elsewhere. 17 All [
11 C]-Pittsburgh compound B (PiB)-PET scans were acquired at Lawrence Berkeley National Laboratory with either a Siemens ECAT EXACT HR PET scanner or Siemens Biograph Truepoint 6 scanner (Siemens Medical Systems, Malvern, PA) in 3-dimensional acquisition mode and a 90-minute dynamic scan as previously reported. 17 Data were analyzed as mean distribution volume ratios as previously reported, with a threshold for PIB positivity of 1.08. 17, 26 Statistical analyses. To validate our factor analysis-derived SCD score, we compared the score to 2 independent subjective memory measurements. 16 The questions were as follows: "How would you rate your memory compared to others your same age?" and "How would you rate your memory compared to yourself 20 years ago?" Participants could rate themselves as better, the same, worse, or much worse. Categories with ,4 respondents were merged with adjacent categories (e.g., worse/much worse). One-way analyses of variance (ANOVAs) were used to assess the relationship between SCD and each subjective memory measurement. Relationships between SCD scores, PiB status, affective score, and demographic variables (age, sex, education, PET scanner, and duration of follow-up) were assessed with correlations, t tests, and Fisher exact tests. Linear models adjusted for age, sex, education, and affective score were used to assess cross-sectional relationships between SCD score and cognition. To better understand some of the underlying constructs contributing to the SCD score, a single linear model was fit with SCD as the dependent variable and age, sex, education, PiB status, family history of AD, global cognition, and affective score as independent variables. Cross-sectional associations between PiB status and cognition were established with linear models adjusted for age, sex, education, and PET scanner.
Mixed models were performed to evaluate the main effects of and interactions between PiB status, SCD, and time on each cognitive variable. These models are robust to missing cognitive data and differing follow-up times. All models used the restricted maximum likelihood method and were fit with an AR(1) covariance structure and type III sum of squares. Denominator degrees of Contribution of SCD, affective features, and brain Ab to cognitive decline. Mixed models were used to assess the effect of SCD, brain Ab, and their interaction on cognition over time, with adjustment for demographic and affective variables. Results for the effects of interest can be found in table 2. A significant 3-way time 3 PiB status 3 SCD interaction was found for episodic memory and global cognition. Plotting these effects revealed that PiB1 individuals exhibited steeper cognitive decline as they demonstrated more severe SCD (figure 2). No 3-way interactions were observed for working memory or processing speed; however, a 2-way SCD 3 time interaction was observed for working memory such that individuals with worse SCD declined more in working memory over time, independently of PiB status (figure 2). Finally, processing speed declined over time independently of other factors. Adjusting models for family history of AD and baseline cognition dropped the 3-way interaction with global cognition to trend levels, although a significant SCD 3 time interaction on global cognition emerged (table e-4). Models including only participants with $3 cognitive testing sessions did not change results (data not shown).
Finally, the same linear mixed models were run, substituting affective score for SCD and instead adjusting for SCD score. No significant 2-or 3-way interactions were observed, although there was a trend-level affective score 3 time interaction for global cognition (table 2). All cognitive variables declined significantly over time. Across all observations, individuals with worse (higher) affective scores tended to demonstrate better cognition.
DISCUSSION Our results add to previous studies that found that both SCD and Ab are related to cognitive decline 1, 7, 8, 11 and suggest that brain Ab and SCD contribute complementary value to the prediction of cognitive decline when both measures are present. Results from our sample suggest that cognitively intact elderly with evidence for brain Ab and SCD undergo objective cognitive decline at a higher rate than individuals with either Ab or SCD alone or neither. This is true despite the fact that individuals with more severe SCD showed evidence of more cognitive impairment at baseline, suggesting that subjective assessments add valuable information over objective cognitive measures. The results were also domain specific: individuals with more severe SCD demonstrated significant cognitive decline in working memory and global cognition independently of Ab, but decline in episodic memory was observed only when both SCD and Ab were present.
Episodic memory is typically the first and most profoundly impaired cognitive domain during the course of AD, 1 and individuals with SCD who later develop dementia show selective impairment in episodic memory over time. 27 While longer follow-up is needed to assess conversion to dementia in the BACS cohort, the presence of brain Ab, SCD, and decline in episodic memory in these individuals is consistent with a profile for preclinical AD. Indeed, our models predicted that PiB1 individuals in the top 80% of SCD scores demonstrate an average rate of decline of 0.18 SD a year in episodic memory and 0.12 SD in global cognition, suggesting a decline of a full SD in only 5 to 8 years. In contrast, PiB2 individuals in the top 80% of SCD score demonstrated little change in cognitive scores over time (0.1 SD/y). These results are convergent with studies finding SCD to be associated with worse cognition in APOE4 carriers compared to noncarriers 9 and studies examining SCD specifically in amyloid-positive participants. 28 The presence of brain Ab alone was not associated with cognitive decline on average. In some cases, PiB1 individuals even showed increases in cognitive test scores over time. These results imply that assessment of both brain Ab and SCD may enable enrichment of clinical trial samples for faster decline over a shorter time period.
Individuals reporting more severe SCD showed declining cognition globally, most markedly in working memory. Working memory deficits in aging are well described, 29 and in cases when Ab is not present, the biology underlying this cognitive decline is unlikely to be related to AD. 30 Instead, white matter abnormalities 31 and frontal lobe integrity 32 have consistently been reported to drive age-related variation in working memory, leading to speculation that vascular dysfunction 32 may contribute to its etiology. Another factor showing a prominent association with working memory in aging is late-life depression. 33 This is an important and relevant consideration because, as with our study, many previous studies have reported a link between SCD and the presence of subtle psychiatric symptoms such as anxiety and subsyndromal depression. 12, 34 This is unlikely to explain our findings, however, because models Table 2 Interactive looking specifically at the contribution of affective scores to cognitive decline failed to find an effect when adjusted for SCD. Our results suggest that associations between GDS scores and cognitive decline in healthy, nondepressed elderly participants may actually be driven by those GDS questions assessing cognitive symptoms rather than depressive symptoms. SCD is a difficult construct to measure because of its very subjectivity. Our study used an unsupervised data-driven method that identified a series of collinear GDS questions relating to subjective cognitive state and related functional complaints, summarized into a weighted SCD score. Our analyses suggest that these complaints may be driven by several independent factors, including symptoms of subsyndromal depression or anxiety, current objective cognitive state, and knowledge of a family history of AD. The last feature may be related to anxiety concerning the knowledge that family history increases risk of AD 35 or could even be a manifestation of preclinical AD symptoms in these high-risk individuals. However, these features together explained only 31% of the variance in SCD and had little bearing on our longitudinal findings when models were adjusted for them. This indicates that individuals may be able to communicate a contextual awareness of cognitive state that goes beyond what a cross-sectional cognitive measurement might reveal. In other words, while SCD and baseline cognition are somewhat collinear, they are not redundant with respect to predicting future cognitive decline. Interactions between PiB status and SCD severity on rate of cognitive change over time (A) Episodic memory, (B) working memory, (C) processing speed, and (D) global cognition. The y-axis of each plot represents the cognitive factor values predicted by the models; the x-axis represents time from baseline. To visualize 3-way interactions, cognition over time is presented separately for PiB2 (blue) and PiB1 (red) groups. These relationships are further split at differing levels of SCD score (panels). Because SCD is a population-normalized variable, panels represent splits in reference to the mean and SD. This is meant only to aid in interpretation of the results. In the actual models, SCD was entered as a scalar variable. Main effects and interactions of interest are given in table 2. GDS 5 Geriatric Depression Scale; PiB 5 Pittsburgh compound B; SCD 5 subjective cognitive decline.
There are several limitations to this study. SCD is currently a field of major interest in aging and AD research, but only recently have there been efforts to standardize its measurement. 6 Therefore, previous studies have used a wide range of instruments to characterize SCD, and our study is no different. The GDS is not specific for SCD, and we recognize that the questions in our SCD factor are not specific to memory loss. However, previous studies have shown that SCD questionnaire items that best distinguish clinical groups or amyloid-positive and -negative groups are not solely memory specific. 22 In addition, the association between our SCD score and independent measures of subjective memory increases confidence in the construct that we are measuring. It is also important to note that our participants were nondepressed, healthy individuals who did not report to a memory clinic for evaluation. 36 Finally, PET scans were recorded on average a year after cognitive baseline. Brain Ab accumulates slowly and is not expected to change much over only a few years, 1 although it is possible that some individuals categorized as PiB2 in this study experienced enough amyloid accumulation over the course of follow-up to transition to PiB1.
Our results provide evidence that cognitively intact elderly with both brain Ab and appreciable SCD are at the greatest risk of decline and clinical impairment. This provides a potential way of enriching the participant sample in clinical trials of Ablowering therapies. The complementary nature and domain specificity with which SCD and Ab predict cognitive decline suggest that they are 2 independent entities. While studies are underway to better understand the relationship of Ab to incipient AD, future studies are required to elucidate the neurobiology underlying the manifestation of SCD and how it may vary according to amyloid status.
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